Published in J Natl Cancer Inst on December 16, 2009
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol (2012) 1.44
Emergency department visits for symptoms experienced by oncology patients: a systematic review. Support Care Cancer (2012) 1.32
Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol (2011) 0.99
Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol (2013) 0.98
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst (2014) 0.94
Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist (2015) 0.93
Long-term Toxicity of Cancer Treatment in Older Patients. Clin Geriatr Med (2015) 0.83
Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF). Front Endocrinol (Lausanne) (2012) 0.81
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol (2016) 0.79
Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet (2012) 0.78
Long-term health effects among testicular cancer survivors. J Cancer Surviv (2016) 0.77
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol (2017) 0.75
The Sound of Silence: A Proxy for Platinum Toxicity. J Clin Oncol (2016) 0.75
Management of stage I testicular germ cell tumours. Nat Rev Urol (2016) 0.75
Optimal management of testicular cancer: from self-examination to treatment of advanced disease. Open Access J Urol (2010) 0.75
A systematic review of patient-reported outcome measures of neuropathy in children, adolescents and young adults. Support Care Cancer (2016) 0.75
Management options for stage 1 nonseminomatous germ cell tumors of the testis. Indian J Urol (2010) 0.75
Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol (2016) 0.75
Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin. Head Neck (2014) 0.75
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol (1997) 8.41
Vascular risk factors and diabetic neuropathy. N Engl J Med (2005) 7.69
Cigarette smoking and hearing loss: the epidemiology of hearing loss study. JAMA (1998) 3.86
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med (1987) 3.52
Combined management of malignant teratoma of the testis. Lancet (1979) 3.12
Chemotherapy-induced peripheral neuropathy. J Neurol (2002) 3.09
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer (2008) 2.55
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol (2006) 1.93
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Paternity following treatment for testicular cancer. J Natl Cancer Inst (2005) 1.87
Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol (2006) 1.85
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80
Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol (2009) 1.65
Raynaud's phenomenon. Lancet (2001) 1.58
Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol (1988) 1.49
Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med (1981) 1.47
Regular review: Managing testicular cancer. BMJ (2001) 1.43
Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol (2007) 1.38
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Combined effect of smoking and occupational exposure to noise on hearing loss in steel factory workers. Occup Environ Med (2003) 1.36
Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer (1985) 1.31
BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol (1991) 1.30
Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol (1996) 1.29
Screened and unscreened hearing threshold levels for the adult population: results from the Nord-Trøndelag Hearing Loss Study. Int J Audiol (2005) 1.26
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer (1998) 1.21
Long-term complications of chemotherapy for germ cell tumours. Drugs (2003) 1.18
Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol (1989) 1.16
Subclinical neuropathy associated with chronic obstructive pulmonary disease: possible pathophysiologic role of smoking. Arch Neurol (1981) 1.14
Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol (1989) 1.12
Prevalence of hearing loss and work-related noise-induced hearing loss in Michigan. J Occup Environ Med (2008) 1.11
Cisplatin-induced hyperactivity in the dorsal cochlear nucleus and its relation to outer hair cell loss: relevance to tinnitus. J Neurophysiol (2002) 1.11
Interaction of smoking and occupational noise exposure on hearing loss: a cross-sectional study. BMC Public Health (2007) 1.09
Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol (2005) 1.09
Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer (1995) 1.05
Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology (1999) 1.05
Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol (1992) 1.05
Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol (1983) 1.04
Cigarette smoking, occupational exposure to noise, and self reported hearing difficulties. Occup Environ Med (2004) 1.02
Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study. Support Care Cancer (1996) 1.00
Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med (2007) 1.00
Response shift: a theoretical exploration of quality of life following hematopoietic cell transplantation. Cancer Nurs (2007) 0.97
Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol (1997) 0.96
Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol (2005) 0.95
Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer (1990) 0.94
Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res (2006) 0.92
Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol (1989) 0.92
High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol (1988) 0.91
The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann Oncol (1999) 0.90
Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer (1990) 0.90
Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol (1990) 0.90
Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology (2006) 0.88
Transient neurological adverse effects following low dose radiation therapy for early stage testicular seminoma. Radiother Oncol (2006) 0.86
Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer (2001) 0.86
External beam abdominal radiotherapy in patients with seminoma stage I: field type, testicular dose, and spermatogenesis. Int J Radiat Oncol Biol Phys (1997) 0.85
Cis-diaminedichloro platinum ototoxicity. An experimental study. Acta Otolaryngol (1985) 0.85
Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv (2008) 0.84
Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology (1995) 0.83
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer (2005) 0.83
Peripheral neuropathies during hypoxaemic chronic obstructive airways disease. Bull Eur Physiopathol Respir (1987) 0.82
Long-term complications of cisplatin-based chemotherapy for testis cancer. Semin Oncol (1988) 0.80
[Peripheral neuropathy associated with chronic obstructive pulmonary disease]. Neurologia (1997) 0.80
Smoking, alcohol consumption, and Raynaud's phenomenon in middle age. Am J Med (2007) 0.79
Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep (1977) 0.77
Association between cigarette and alcohol consumption and Raynaud's phenomenon. J Clin Epidemiol (1999) 0.76
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol (2012) 3.95
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol (2008) 3.29
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol (2013) 2.73
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol (2002) 2.65
Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord (2006) 2.47
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res (2008) 2.37
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol (2007) 2.17
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res (2005) 2.04
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer (2008) 1.95
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.93
[Should complementary therapies be offered in hospitals?]. Tidsskr Nor Laegeforen (2004) 1.91
Paternity following treatment for testicular cancer. J Natl Cancer Inst (2005) 1.87
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol (2004) 1.85
Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur Urol (2006) 1.78
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Post-traumatic stress reactions in survivors of the 2011 massacre on Utøya Island, Norway. Br J Psychiatry (2013) 1.73
Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol (2011) 1.73
Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol (2003) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Growth of untreated vestibular schwannoma: a prospective study. J Neurosurg (2012) 1.66
Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol (2009) 1.65
Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys (2012) 1.58
A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int (2012) 1.57
Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology (2005) 1.53
Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer (2009) 1.52
Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res (2005) 1.52
Long-term cardiac mortality after hypofractionated radiation therapy in breast cancer. Int J Radiat Oncol Biol Phys (2013) 1.52
A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer (2008) 1.50
Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Transfusion (2009) 1.50
Factors complicating interpretation of capnography during advanced life support in cardiac arrest--a clinical retrospective study in 575 patients. Resuscitation (2012) 1.50
The other side of the coin: perceived positive effects of illness in women following acute myocardial infarction. Eur J Cardiovasc Nurs (2007) 1.48
Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res (2010) 1.45
Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol (2004) 1.45
The rate of cognitive decline in Parkinson disease. Arch Neurol (2004) 1.44
Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol (2010) 1.43
Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol (2014) 1.42
Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer (2010) 1.42
Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res (2007) 1.41
[Does use of alternative medicine aggravate the survival prognosis in cancer?]. Tidsskr Nor Laegeforen (2003) 1.40
Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Int (2011) 1.39
The relation between arm/shoulder problems and quality of life in breast cancer survivors: a cross-sectional and longitudinal study. J Cancer Surviv (2010) 1.37
Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int (2008) 1.37
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncol (2008) 1.36
Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol (2010) 1.36
Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate (2012) 1.33
Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord (2008) 1.33
Altered interhemispheric connectivity in individuals with Tourette's disorder. Am J Psychiatry (2004) 1.31
Self-reported health and use of health care services in long-term cancer survivors. Int J Cancer (2005) 1.29
The coping styles of adolescents with type 1 diabetes are associated with degree of metabolic control. Diabetes Care (2004) 1.28
The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology (2009) 1.28
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One (2011) 1.28
Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol (2006) 1.27
Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med (2011) 1.27
Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol (2012) 1.26
Assessment of male sexual function by the Brief Sexual Function Inventory. BJU Int (2006) 1.25
New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res (2002) 1.25
A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol (2006) 1.25
Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer (2011) 1.24
The day Norway cried: Proximity and distress in Norwegian citizens following the 22nd July 2011 terrorist attacks in Oslo and on Utøya Island. Eur J Psychotraumatol (2012) 1.24
Suicide after breast cancer: an international population-based study of 723,810 women. J Natl Cancer Inst (2006) 1.23
Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res (2003) 1.21
Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol (2003) 1.20